Author of

• 20164

  +

  P1.15 - SCLC/Neuroendocrine Tumors (ID 701)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22800

    +

    P1.15-015 - Prognostic Implication of the FEV1/FVC Ratio in Limited-Stage Small Cell Lung Cancer (ID 7873)

    09:30 - 09:30  |  Author(s): J. Heo
    • Abstract
    • Slides

    Background:
    The aim of this study was to evaluate whether the pretreatment forced expiratory volume 1 (FEV1)/forced volume vital capacity (FVC) ratio could predict survival in patients with limited-stage small cell lung cancer (LS-SCLC).
    
    Method:
    We assessed 74 patients with LS-SCLC treated with chemoradiotherapy who were divided into two groups: those with FEV1/FVC <0.74 (n=24) and those with FEV1/FVC ≥0.74 (n=50).
    
    Result:
    The 3-year overall survival (OS) and 3-year progression-free survival (PFS) rates were significantly lower in patients with FEV1/FVC ratios <0.74 than in those with ratios ≥0.74 group (35.4% vs. 61.2%, P=0.0033; and 11.7% vs. 51.8%, P=0.0072, respectively). On multivariate analysis, a low FEV1/FVC ratio was independently associated with OS and PFS (hazard ratio [95% confidence interval]: 2.15 [0.99–4.63], P=0.052; and 2.13 [1.04–4.39], P=0.039, respectively).
    
    Conclusion:
    The pretreatment FEV1/FVC ratio appears to be a potential prognostic factor for LS-SCLC.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.